Press releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Sep 23, 2014Data From REPRISE III Clinical Trial Designed to Support U.S. Regulatory Approval
Boston Scientific Corporation (NYSE: BSX) has initiated the REPRISE III clinical trial, a pivotal study to evaluate the safety and effectiveness of the Lotus™ Valve System in patients with...
-
Sep 17, 2014Vercise DBS System is the First DBS System Offering Precise Neural Targeting and a 25-Year Battery Life
Boston Scientific Corporation (NYSE: BSX) has received CE Mark for the Vercise™ Deep Brain Stimulation (DBS) System for the treatment of tremor, including the most common form of this movement...
-
Sep 15, 2014No Cases of Moderate or Severe Paravalvular Aortic Regurgitation at One Year
New data from the Boston Scientific (NYSE: BSX) clinical trial program of the Lotus™ Valve System continue to demonstrate strong performance as a less invasive treatment for patients with severe...
-
Sep 10, 2014Data Will Focus on Areas of Significant Unmet Patient Need, Including Coronary Artery Disease and Aortic Valve Disease
Beginning Saturday, Boston Scientific Corporation (NYSE: BSX) will present data that reinforce the company's commitment to advancing science for life and to developing innovative therapies in...
-
Sep 3, 2014
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2014 Bank of America Merrill Lynch Global Healthcare Conference on September 17, 2014 in London, England. Michael...
-
Sep 2, 2014
Boston Scientific Corporation (NYSE: BSX) closed on its previously announced agreement to purchase the Interventional business of Bayer AG. The acquisition enhances the ability of Boston...
-
Aug 30, 2014Phase II feasibility trial provides first randomized sham-controlled data using vagus nerve stimulation to treat heart failure
Boston Scientific has released the primary endpoint results from its NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) clinical trial, the first and only randomized sham-controlled clinical...
-
Aug 25, 2014
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2014 Morgan Stanley Global Healthcare Conference on September 8 in New York, NY. Mike Mahoney, chief executive officer, and
-
Aug 19, 2014Companies Reach Agreement to Develop a New and Differentiated FFR Guidewire and Next Generation Boston Scientific Rotablator™ RotaWire™
Boston Scientific Corporation (NYSE: BSX) and ASAHI INTECC (Securities Code 7747, Second Section, Tokyo and Nagoya Stock Exchange) have formalized plans to develop a new, differentiated fractional...
-
Jul 24, 2014
Boston Scientific Corporation (NYSE: BSX) generated sales of $1.873 billion during the second quarter ended June 30, 2014, compared to the company's guidance range for the quarter of $1.840 to...